Magle Chemoswed has been approved for listing on Nasdaq First North and publishes a supplementary document

Magle Chemoswed has, as previously announced, carried out an offer to the public in Sweden and institutional investors to acquire existing shares in the Company at an amount corresponding to SEK 50 million. The offer was oversubscribed and in total the Company got approximately 1500 new shareholders. The audit of the Magle Chemoswed is now complete and the Nasdaq has approved Magle Chemosweds admission to on Nasdaq First North.

As a result of the listing on the Nasdaq First North Growth Market, the Company has prepared an additional document which is available on Magle Chemoswed's website, www.maglechemoswed.com. The supplementary document shall be read as a supplement to the Prospectus published in connection with the Offer in June 2020. The supplementary document is not a prospectus, has not been reviewed or approved by any regulatory authority and does not contain any offering of shares or other financial instruments.

For more information, please contact
Justin Pierce, CEO, Magle Chemoswed Holding AB
Tel: +46 46 (0)70 59 358 21 
Email: Justin.Pierce@maglechemoswed.com
About us
We are Magle Chemoswed, a Malmö-based contract development and manufacturing organization (CDMO) that serves companies in the pharmaceutical and medical device industry on a contract basis. We provide comprehensive services from product development through product manufacturing and we pride ourselves in coming up with solutions to complex healthcare challenges. Together with our customers, we take innovations from idea to product. Learn more on www.maglechemoswed.com.

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.